Pharmaceutical nanotechnology
Figure 14.1 Nanosystems that exist in nature (not to scale). Left to right: an insulin hexamer (3.5 × 5 nm), a low-density lipoprotein (LDL) particle (28 nm) and a parvovirus (20–25 nm). LDL…
Paediatric and geriatric formulations
Figure 10.1 The matrix of drivers for special formulations. 10.2 Paediatric medication Children are far from being a homogeneous group. They range from: preterm newborn infants (premature: average weight <3.4 kg) full-term…
Generic medicines and biosimilars
Key point The search for true bioequivalence is important. Given the variability of human drug response, to which we have referred several times, it is even more important that the product…
Physical assessment of dosage forms
15 Physical assessment of dosage forms It is important to have means of studying the key characteristics of quality of formulations during development and for quality control purposes during production…
Surfactants
5 Surfactants Certain compounds, because of their chemical structure, have a tendency to accumulate at the boundary between two phases. Such compounds are termed amphiphiles, surface-active agents or surfactants. Their…
